Tokyo (January 7, 2002) - Eisai Co., Ltd. of Tokyo (President and CEO: Haruo Naito) announced the application today for an indication expansion of PARIET, an antiulcer medication, for the treatment of gastroesophageal reflux disease (GERD).
PARIET has already received approval for the treatment of gastroesophageal reflux disease, but the treatment term has been limited to eight weeks. Today's application seeks approval for extended treatment for maintenance therapy of recurrent GERD. In Europe and the U.S., the product has already been approved for GERD maintenance therapy.
In gastroesophageal reflux disease, reflux of acidic stomach contents results in erosion and swelling of the esophageal mucosa causing symptoms such as frequent heartburn, and dyspepsia. Because even after successful therapy recurrence is common, maintenance therapy is considered very important. In recent years in Europe and the U.S. as well as in Japan, there has been a reported increase in the number of patients suffering from gastroesophageal reflux disease.
PARIET was first launched in Japan in 1997, in Europe in 1998, and in the U.S. in 1999 under the trade name ACIPHEX . As of October 2001, PARIET had been approved in 77 countries and launched in 59 countries. Global sales of the product are expected to be approximately 84.0 billion (excluding licensed territories) in the current fiscal year.
Eisai Co., Ltd. is a research-based human health care company which discovers, develops and markets products in more than 30 countries. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. The company reported sales of over $2.9 billion in 2000 with approximately 14 percent of sales spent for research and development.
PARIET is a registered trademark of Eisai Co., Ltd.
ACIPHEX is a registered trademark of Eisai Co., Ltd.